Revelation Biosciences Had $17.7M In Cash And Cash Equivalents As Of Mar. 31
Portfolio Pulse from Benzinga Newsdesk
Revelation Biosciences reported having $17.7 million in cash and cash equivalents as of March 31.
May 22, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Revelation Biosciences (REVB) had $17.7 million in cash and cash equivalents as of March 31.
Revelation Biosciences' cash and cash equivalents position is a key financial metric for investors. However, the news does not provide any context or comparison to previous periods, making it difficult to assess the impact on the stock price in the short term. Therefore, the score is neutral.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100